BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 17290328)

  • 1. [Cytokine-based and targeted therapy of metastatic renal cell carcinoma--a current analysis].
    Johannsen M; Ringsdorf M; Römer A; Loening SA; Roigas J
    Aktuelle Urol; 2007 Jan; 38(1):38-45. PubMed ID: 17290328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy of renal cell cancer.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
    Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
    J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
    Kwan KG; Kapoor A
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Systemic therapy for metastatic renal cell carcinoma].
    Kramer MW; Steffens S; von Klot C; Merseburger AS; Kuczyk MA
    Aktuelle Urol; 2012 Jul; 43(4):265-8. PubMed ID: 22869498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drug therapies for advanced renal cell carcinoma.
    Gore ME; Harrison ML; Montes A
    Expert Rev Anticancer Ther; 2007 Jan; 7(1):57-71. PubMed ID: 17187520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.
    Ainsworth NL; Lee JS; Eisen T
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?
    Brookman-May S; May M; Gilfrich C; Wieland WF; Burger M
    Expert Rev Anticancer Ther; 2010 Jun; 10(6):813-23. PubMed ID: 20553207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving outcomes in patients with advanced renal cell carcinoma.
    Sosman JA
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):481-90. PubMed ID: 18366295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New treatments for metastatic kidney cancer.
    Mancuso A; Sternberg CN
    Can J Urol; 2005 Feb; 12 Suppl 1():66-70; discussion 105. PubMed ID: 15780170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community.
    Bukowski RM
    Oncology (Williston Park); 2006 May; 20(6 Suppl 5):25-8. PubMed ID: 16773842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current immunotherapeutic strategies in renal cell carcinoma.
    Amato RJ
    Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment for renal cancer: are we beyond the cytokine era?
    Ramsey S; Aitchison M
    Nat Clin Pract Urol; 2006 Sep; 3(9):478-84. PubMed ID: 16964189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New entities in pathological classification and new therapeutic options in renal cell carcinoma].
    Bay JO; Penault-Llorca F; Ravaud A; Chevreau C; Négrier S; Escudier B
    Bull Cancer; 2006 Jan; 93(1):91-100. PubMed ID: 16455511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EORTC-GU group expert opinion on metastatic renal cell cancer.
    de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
    Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatment approaches in renal cell carcinoma.
    Facchini G; Perri F; Caraglia M; Pisano C; Striano S; Marra L; Fiore F; Aprea P; Pignata S; Iaffaioli RV
    Anticancer Drugs; 2009 Nov; 20(10):893-900. PubMed ID: 19752718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining an individualized treatment strategy for metastatic renal cancer.
    Hu B; Lara PN; Evans CP
    Urol Clin North Am; 2012 May; 39(2):233-49, vii. PubMed ID: 22487765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
    Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
    Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy for renal cell carcinoma: a new therapeutic paradigm.
    Shaheen PE; Bukowski RM
    Cancer Invest; 2006 Oct; 24(6):640-56. PubMed ID: 16982470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.